Overview

A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy

Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine whether CVL-871 is safe and tolerable in patients with Dementia-Related Apathy and if CVL-871 shows changes in clinical measurements of apathy.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Cerevel Therapeutics, LLC
Criteria
Inclusion Criteria:

- Meets diagnostic criteria for apathy in neurocognitive disorders clinically
significant apathy

- Mild to Moderate Dementia (AD, FTD, VAD, or DLB)

Exclusion Criteria:

- Other significant psychiatric disorder(s)

- Other neurological disorders (other than AD, FTD, VAD, or DLB)